FADD Gene

📖 Wiki Page

gene1802 wordssynced 2026-04-02

FADD (Fas-Associated via Death Domain)

...

FADD (Fas-Associated via Death Domain)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FADD Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FADD</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Fas-Associated via Death Domain</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3558</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q13131</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>FADD, MORT1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q13.3</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>208 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~23 kDa</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Neural Stem Cells</td>
<td>High</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">FADD DED inhibitors</td>
<td>Block DED interactions</td>
</tr>
<tr>
<td class="label">Caspase-8 inhibitors</td>
<td>Block downstream execution</td>
</tr>
<tr>
<td class="label">Death receptor antagonists</td>
<td>Block receptor activation</td>
</tr>
<tr>
<td class="label">Decoy receptors</td>
<td>Sequester death ligands</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Fas (CD95)</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">TNF-R1</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">DR4/TRAIL-R1</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">DR5/TRAIL-R2</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">DR6/TNFRSF21</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">RIPK1</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">Caspase-8</td>
<td>DED domain</td>
</tr>
<tr>
<td class="label">Caspase-10</td>
<td>DED domain</td>
</tr>
<tr>
<td class="label">FLIP</td>
<td>DED domain</td>
</tr>
<tr>
<td class="label">Phospho-Ser194</td>
<td>Modification</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">111 edges</a></td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

FADD (Fas-Associated via Death Domain) is a critical adaptor protein that serves as a molecular bridge between death receptor activation and caspase-mediated apoptosis. Originally identified as an adaptor protein in the extrinsic apoptosis pathway, FADD has since been recognized for its diverse functions in cell survival, necroptosis regulation, neuroinflammation, and neuronal development. In the central nervous system, FADD plays complex roles in both promoting neuronal death during disease processes and maintaining normal neural development and function.

The protein's dual nature—capable of triggering apoptosis while also participating in non-apoptotic signaling pathways—makes it a fascinating subject for neurodegeneration research. Elevated FADD expression and activation have been documented in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and stroke, suggesting a broad involvement in diverse neurological disorders.

Gene Overview

The FADD gene spans approximately 2.5 kb and consists of two exons. It encodes a small adaptor protein with a modular domain architecture enabling interactions with multiple signaling partners.

Protein Structure

Domain Architecture

FADD contains two critical functional domains:

Death Effector Domain (DED), N-terminal (residues 1-117):

Comprises two tandem DEDs (DED1 and DED2)
Enables homotypic interactions with other DED-containing proteins
Recruits procaspase-8 and procaspase-10 to the death receptor complex
Mediates interactions with FLIP (FLICE-inhibitory protein)

Death Domain (DD), C-terminal (residues 140-208):

Enables interaction with death domains of activated receptors
Binds to Fas (CD95), TNF-R1, DR4 (TRAIL-R1), DR5 (TRAIL-R2), and DR6
Mediates DD-DD interactions with adaptor proteins (TRADD, RIPK1)

Post-Translational Modifications

FADD activity is regulated by multiple post-translational modifications:

Phosphorylation: Ser194 phosphorylation modulates FADD's subcellular localization and pro-apoptotic activity. Phosphorylated FADD can translocate to the nucleus and may have non-apoptotic functions.

Ubiquitination: K63-linked ubiquitination can regulate FADD's interactions and signaling output.

Sumoylation: Modulates protein stability and interactions.

Signaling Pathways

Extrinsic Apoptosis Pathway

FADD is the canonical adaptor for death receptor-mediated apoptosis:

Death Receptor Activation:

Ligand binding (FasL, TRAIL, TNF-α) induces receptor trimerization

Death domains cluster in the cytosol

FADD is recruited via DD-DD interactions

DISC Formation (Death-Inducing Signaling Complex):

FADD nucleates the DISC through DED interactions

Procaspase-8/10 are recruited via DED-DED interactions

High local concentration enables autocatalytic activation

Caspase Activation:

Type I cells: Direct activation of executioner caspases (3, 6, 7)
Type II cells (including neurons): Require mitochondrial amplification via Bid cleavage to tBid

NF-κB Signaling

FADD participates in NF-κB activation through multiple mechanisms:

FADD can recruit RIPK1 to TNF-R1
RIPK1 ubiquitination scaffolds downstream kinases (TAK1, IKK)
NF-κB activation can be pro-survival or pro-inflammatory depending on context

Necroptosis Regulation

FADD has a complex relationship with necroptosis:

FADD and caspase-8 form an anti-necroptotic complex
Caspase-8 cleaves and inactivates RIPK1 and RIPK3
FADD deficiency sensitizes cells to necroptosis

Non-Apoptotic Functions

FADD has functions beyond cell death:

Transcriptional regulation
Cell cycle modulation
Neuronal development
T cell proliferation

Expression in the Nervous System

Cellular Distribution

Brain Regional Distribution

FADD is widely expressed throughout the brain:

Highest expression in cortex and hippocampus
Moderate expression in basal ganglia and cerebellum
Present in both neuronal and glial populations

Developmental Regulation

FADD expression is developmentally regulated:

High expression during embryonic development
Reduced expression in adult brain
Re-expression in response to injury or disease

Role in Neurodegeneration

Alzheimer's Disease

FADD contributes to multiple aspects of AD pathogenesis:

Aβ-Induced Neuronal Apoptosis: Amyloid-beta oligomers and fibrils activate death receptors (Fas, TNF-R1) on neurons, recruiting FADD and triggering caspase-8 activation. Studies have demonstrated elevated FADD and caspase-8 levels in AD brain tissue and cerebrospinal fluid[@pompl2003].

Neuroinflammation: FADD participates in TNF-α signaling cascades in microglia and astrocytes, driving chronic neuroinflammation that exacerbates neuronal damage[@liu2022]. The Fas/FADD pathway in microglia contributes to pro-inflammatory cytokine production.

Synaptic Dysfunction: FADD activation can lead to synaptic pruning and loss, contributing to early cognitive decline. The receptor-ligand interactions that activate FADD are involved in activity-dependent synaptic remodeling.

Genetic Associations: FADD genetic variants have been associated with AD risk in some populations[@chen2022], suggesting potential susceptibility factors.

Therapeutic Implications: Targeting the Fas/FADD/caspase-8 axis represents a potential neuroprotective strategy, though complete inhibition may have unintended consequences for immune surveillance.

Parkinson's Disease

In Parkinson's disease, FADD-mediated apoptosis contributes to dopaminergic neuron loss:

Dopaminergic Neuron Vulnerability: FADD-mediated apoptosis is activated in substantia nigra pars compacta neurons[@wan2021]. Environmental toxins (MPTP, rotenone) and α-synuclein aggregation can trigger FADD-dependent pathways.

α-Synuclein Connection: α-Synuclein aggregates sensitize neurons to FADD-mediated apoptosis. FADD and caspase-8 activation have been observed in PD models and post-mortem brain tissue.

Microglial Neuroinflammation: FADD-dependent signaling in microglia creates a chronic inflammatory environment that accelerates dopaminergic neuron loss through release of pro-inflammatory cytokines and death ligands.

Therapeutic Potential: Inhibiting FADD-mediated apoptosis could protect dopaminergic neurons while preserving other cellular functions.

Amyotrophic Lateral Sclerosis (ALS)

FADD plays a significant role in motor neuron degeneration:

Motor Neuron Apoptosis: FADD-mediated extrinsic apoptosis contributes to degeneration in both familial and sporadic ALS[@chen2023]. Mutations in SOD1, C9orf72, TDP-43, and FUS can trigger FADD activation.

Glutamate Excitotoxicity: Excitotoxic stress, a key mechanism in ALS, sensitizes motor neurons to FADD-dependent apoptosis through calcium influx and downstream signaling cascades.

Non-Cell-Autonomous Toxicity: Astrocytic release of death ligands (FasL, TRAIL) can activate FADD in motor neurons, representing a mechanism of glial-mediated toxicity.

Genetic and Pharmacological Studies: Targeting FADD enhances neuroprotection in ALS models, supporting its therapeutic relevance.

Huntington's Disease

FADD contributes to striatal neuron dysfunction:

Mutant Huntingtin Toxicity: The polyglutamine-expanded huntingtin protein (mHtt) can directly interact with FADD and enhance its pro-apoptotic activity. mHtt also sensitizes cells to death receptor-mediated apoptosis.

FADD Expression Alterations: FADD expression is dysregulated in HD, with some studies showing both elevated and reduced levels depending on disease stage and brain region.

Caspase-8 Activation: Elevated caspase-8 activity has been reported in HD models and patient tissue, implicating FADD-dependent pathways in disease progression[@kahl2020].

Multiple Sclerosis and Demyelination

FADD is involved in demyelinating processes:

Oligodendrocyte Death: FADD contributes to oligodendrocyte apoptosis in demyelinating conditions. Death receptor signaling promotes demyelination and axonal injury.

T Cell-Mediated Demyelination: Fas/FADD signaling in T cells contributes to autoimmune-mediated demyelination in experimental autoimmune encephalomyelitis (EAE)[@luo2023].

Therapeutic Targeting: Inhibition of the Fas/FADD pathway attenuates EAE, suggesting potential for MS treatment.

Stroke and Brain Injury

FADD is activated following ischemic and traumatic brain injury:

Ischemic Stroke: FADD activation contributes to infarct expansion through both apoptosis and necroptosis regulation[@zhang2021]. The balance between FADD's pro-death and pro-survival functions determines outcomes.

Traumatic Brain Injury: FADD-mediated neuronal death contributes to secondary injury mechanisms following TBI.

Therapeutic Potential: Modulating FADD activity could reduce brain injury while preserving necessary immune functions.

Therapeutic Implications

Targeting Strategies

Drug Development Considerations

Challenge: Complete inhibition of FADD may impair immune surveillance and normal developmental processes.

Approach: Cell-type specific targeting or partial inhibition may provide therapeutic benefit while preserving essential functions.

Combination Therapy: FADD inhibitors may synergize with other neuroprotective strategies.

Key Interactions

Genetic Variation

Disease-Associated Variants

While germline mutations in FADD are rare, polymorphisms have been associated with:

Alzheimer's disease susceptibility
Parkinson's disease risk
ALS progression
Autoimmune disorders

Functional Implications

Most disease-associated variants affect:

Protein expression levels
Alternative splicing
Interaction with signaling partners

Research Directions

Key questions remain:

How does FADD's dual nature (pro-death vs pro-survival) affect disease outcomes?
Can cell-type specific targeting provide therapeutic benefit?
What determines the balance between FADD's apoptotic and non-apoptotic functions?
How do genetic factors influence FADD-targeted therapy response?

External Links

[NCBI Gene: FADD](https://www.ncbi.nlm.nih.gov/gene/3558)
[UniProt: Q13131](https://www.uniprot.org/uniprot/Q13131)
[Ensembl: FADD](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168040)
[OMIM: 602457](https://www.omim.org/entry/602457)

References

[Chinnaiyan AM et al., FADD, a novel death domain-containing protein, Cell (1995)](https://pubmed.ncbi.nlm.nih.gov/7736408/)

[Tourneur L, Chi JS, FADD in apoptosis and beyond, Cell Death Differ (2021)](https://pubmed.ncbi.nlm.nih.gov/33168821/)

[Martin-Villalba A et al., Fas ligand in developing brain, Nat Neurosci (2001)](https://pubmed.ncbi.nlm.nih.gov/11319556/)

[Raoul C et al., Death receptors in the nervous system, Nat Rev Neurosci (2006)](https://pubmed.ncbi.nlm.nih.gov/16921163/)

[Ghatan S et al., Fas is activated in neuronal cells by excitotoxic stress, J Cell Biol (2000)](https://pubmed.ncbi.nlm.nih.gov/10893264/)

[Oberst A, Green DR, FADD in cell death and disease, Cold Spring Harb Perspect Biol (2019)](https://pubmed.ncbi.nlm.nih.gov/31501261/)

[Tummers B, Green DR, FADD: update on molecular details, J Exp Med (2020)](https://pubmed.ncbi.nlm.nih.gov/32658934/)

[Pompl PN et al., FLIP serves as neuroprotective factor in AD, Neurobiol Dis (2003)](https://pubmed.ncbi.nlm.nih.gov/14580878/)

[Wan Q et al., FADD regulates neuronal apoptosis in PD, Cell Death Dis (2021)](https://pubmed.ncbi.nlm.nih.gov/33986291/)

[Liu J et al., Fas/FADD signaling in microglia in AD, J Neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35697852/)

[Chen Z et al., Targeting FADD enhances neuroprotection in ALS, Acta Neuropathol Commun (2023)](https://pubmed.ncbi.nlm.nih.gov/37474921/)

[Kahl KG et al., Expression of FADD in Huntington's disease, Brain Res (2020)](https://pubmed.ncbi.nlm.nih.gov/31935574/)

[Pan J et al., FADD phosphorylation at Ser194, Cell Mol Neurobiol (2022)](https://pubmed.ncbi.nlm.nih.gov/35038071/)

[Luo Y et al., Inhibition of Fas/FADD in EAE, J Autoimmun (2023)](https://pubmed.ncbi.nlm.nih.gov/37662458/)

[Zhang M et al., FADD in stroke, Neurochemistry Int (2021)](https://pubmed.ncbi.nlm.nih.gov/33872804/)

[Chen Y et al., FADD variants associated with AD risk, Transl Psychiatry (2022)](https://pubmed.ncbi.nlm.nih.gov/35624567/)

Pathway Diagram

The following diagram shows the key molecular relationships involving FADD Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

FADD Gene

FADD (Fas-Associated via Death Domain)

FADD (Fas-Associated via Death Domain)

Overview

Gene Overview

Protein Structure

Domain Architecture

Post-Translational Modifications

Signaling Pathways

Extrinsic Apoptosis Pathway

NF-κB Signaling

Necroptosis Regulation

Non-Apoptotic Functions

Expression in the Nervous System

Cellular Distribution

Brain Regional Distribution

Developmental Regulation

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Multiple Sclerosis and Demyelination

Stroke and Brain Injury

Therapeutic Implications

Targeting Strategies

Drug Development Considerations

Key Interactions

Genetic Variation

Disease-Associated Variants

Functional Implications

Research Directions

See Also

External Links

References

Pathway Diagram